MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17

Experimental Cell Research

Volumn 318, Issue 17, 2012, Pages 2168-2177

  Xu, Ke ^a   Liang, Xin ^a   Shen, Ke ^a   Sun, Liyun ^a   Cui, Daling ^a   Zhao, Yuxia ^a   Tian, Jianhui ^b   Ni, Lei ^c   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ADAM 17; Colorectal carcinoma; EGFR; MiR 222; Multidrug resistance (MDR); TGF

Indexed keywords

LUCIFERASE; MICRORNA 222; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

3' UNTRANSLATED REGION; ARTICLE; CANCER RESISTANCE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84864820077     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.04.014     Document Type: Article

References (33)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global Cancer Statistics. CA: A Cancer J. Clin. 2011, 61:69-90.
2. Kuwai T., Nakamura T., Sasaki T., Kitadai Y., Kim J.S., Langley R.R., Fan D., Wang X., Do K.A., Kim S.J., Fidler I.J. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin. Exp. Metastasis 2008, 25:477-489.
3. Gschwind A., Fischer O.M., Ullrich.A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4:361-370.
4. Blobel.C.P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell. Biol. 2005, 6:32-43.
5. Duffy M.J., Lynn D.J., Lloyd A.T., O'Shea C.M. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb. Haemostasis 2003, 89:622-631.
6. Kyula J.N., Van Schaeybroeck S., Doherty J., Fenning J.S., Longley D.B., Johnston P.G. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res. 2010, 16:3378-3389.
7. Nicoloso M.S., Spizzo R., Shimizu M., Rossi S. G.A. Calin MicroRNAs-the microsteering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9:293-302.
8. Krutzfeldt J., Poy M.N., Stoffel M. Strategies to determine the biological function of microRNAs. Nat. Genet. 2006, 38:S14-S19.
9. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
10. Cho.W.C. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 2007, 6:60.
11. Chen C.Z. MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 2005, 353:1768-1771.
12. Hu X., Macdonald D.M., Huettner P.C., Feng Z., Naqa I.M., Schwarz J.K., Mutch D.G., Grigsby P.W., Powell S.N., Wang X. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer Gynecol. Oncol. 2009, 114:457-464.
13. Xie J., Lu J., Kulbokas E.J., Golub T.R., Mootha V., Lindblad T.K., Lander E.S., Kellis M. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 2005, 434:338-345.
14. Zhu H., Wu H., Liu X., Evans B.R., Medina D.J., Liu C.G. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression inhuman cancer cells. Biochem. Pharmacol. 2008, 76:582-588.
15. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 2008, 7:2152-2159.
16. Zhong X.L., Hui W., James X., Yu H.L., Ya W.Z., Ke H., Nicholas W., Younghyoun Y., Choa H.T., Scalae S., Hyunsuk S. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 2010, 79:817-824.
17. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., Barbisin M., Xu N.L., Mahuvakar V.R., Andersen M.R., Lao K.Q., Livak K.J., Guegler K.J. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33:e179.
18. Moss M.L., Jin S.L., Milla M.E. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
19. Huovila A.P., Turner A.J., Pelto-Huikko M., Karkkainen I., Ortiz R.M. Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 2005, 30:413-422.
20. Zhao J., Chen H., Peschon J.J., Shi W., Zhang Y., Frank S.J., Warburton D. Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev. Biol. 2001, 232:204-218.
21. Shi W., Chen H., Sun J., Zhao J., Anderson K.D., Williams R.G., Warburton D. TACE is required for fetal murine cardiac development and modeling. Dev. Biol. 2003, 261:371-380.
22. Blanchot-Jossic F., Jarry A., Masson D., Bach-Ngohou K., Paineau J., Denis M.G., Laboisse C.L., Mosnier J.F. Up-regulated expression of ADAM-17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J. Pathol. 2005, 207:156-163.
23. Katrin H., Zhi X., Clemens F., Elvira M., Susanne S., Markus W.B., Peter S. Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell Int. 2011, 11:40.
24. Elizabeth A.H.B., Rochelle E.N., Vladimir R., Louis M.W., Erica A.G., Igor A. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin. Ther. Targets. 2009, 13:339-362.
25. Gregory R.I., Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005, 65:3509-3512.
26. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C., Kipps T.J., Negrini M., Croce.C.M. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A 2005, 102:13944-13949.
27. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. MiR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
28. Kent O.A., Mendell.J.T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
29. Pan Y.Z., Morris M.E., Yu.A.M. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 2009, 75:1374-1379.
30. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., Hong L., Liu J., Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123:372-379.
31. Liang Z., Wu H., Reddy S., Zhua A., Wanga S., Blevinsa D., Yoona Y., Zhanga Y., Shima H. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem. Biophys. Res. Commun. 2007, 363:542-546.
32. Dickins R.A., Hemann M.T., Zilfou J.T., Simpson D.R., Ibarra I., Hannon G.J., Lowe S.W. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 2005, 37:1289-1295.
33. Tsuda N., Kawano K., Efferson C.L., Ioannides C.G. Synthetic microRNA and double-stranded RNA targeting the 30-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells. Int. J. Oncol. 2005, 27:1299-1306.